View Sample PDF

The medical imaging segments are poised for a major new phase of growth fueled by the availability of new technology coming out of the computer and digital information technology segment. Continuous improvements in technology are resulting in a growing number of new imaging tests that combine high levels of accuracy with rapid, easy-to-use product formats. Part of that medical imaging improvement is coming from positron emission tomography (PET). PET is a scanning technique used in combination with small amounts of radio-labeled compounds to visualize the anatomy and function of the brain. The purpose of this TriMark Publications report is to describe the specific market segment of the diagnostics medical imaging market called PET scanning. This sector includes all of the generally accepted imaging activities that are currently used in PET, including equipment for PET, PET/CT, SPECT and the use of radiopharmaceuticals for imaging. It examines these clinical measurement devices and their reagents and supplies as used in hospitals and clinics. It also reviews associated clinical market segments in which PET scanning has taken a prominent role including cancer treatment, cardiology, and neurology imaging markets.

1. 1 Overview 4
2. 1.1 Statement of Report 4
3. 1.2 Scope of this Report 4
4. 1.3 Methodology 5
5. 1.4 Executive Summary 6
7. 2 Overview of the Medical Imaging Market 8
8. 2.1 Medical Imaging Industry Market Size 8
9. 2.2 Medical Imaging Infrastructure 9
10. 2.2.1 Total Healthcare Expenditures and Demographics 9
11. 2.2.2 Number of Hospitals 11
12. 2.2.3 Number of Radiologists 12
13. 2.2.4 Radiologic Services 13
14. 2.2.5 Medical Imaging Companies 15
15. 2.2.6 Medical Imaging Market Drivers 15
16. 2.2.7 Market Restraints 16
17. 2.2.8 Market Segments for PET Imaging 17
18. 2.2.9 Key Players in the PET Imaging Segment 22
19. 2.2.10 Medical Imaging Sector Analysis 24
20. 2.3 Structure and Use of PET Imaging 25
21. 2.3.1 Functional Imaging versus Anatomic Imaging 25
22. 2.3.2 Functional Imaging Using Single-Photon Imaging (SPECT) 26
23. 2.3.3 PET in Clinical Use 29
24. 2.3.4 PET Sensitivity 30
25. 2.3.5 Therapeutic Uses of PET 30
26. 2.3.6 PET/CT 30
27. 2.3.7 The Future of PET in Cancer Imaging 31
28. 2.3.8 PET Reimbursement 31
29. 2.4 Radiopharmaceutical Imaging 32
30. 2.4.1 Cardinal Health Acquires PET Radiopharmaceutical Production Facilities 33
31. 2.4.2 GE Healthcare Launches New Platform for Automated Synthesis of PET Radiopharmaceuticals 33
32. 2.4.3 Siemens Medical PETNET Radiopharmacy 34
33. 2.4.4 Future Growth of PET Imaging Procedures 34
34. 2.4.5 Diagnostic Radiopharmaceuticals: Market Analysis and Future Prospects 34
35. 2.4.6 New Radiopharmaceutical Applications 35
37. 3 PET Market 37
38. 3.1 Market Size 37
39. 3.2 Total PET and PET/CT Market Trends 37
40. 3.2.1 Market Segmentation and Definitions 38
41. 3.2.2 Overview 38
42. 3.2.3 Market Measurements 39
43. 3.2.4 Market Drivers 40
44. 3.2.5 Market Restraints 41
45. 3.2.6 Future Needs for Market Development 42
46. 3.2.7 Clinical Usages 42
47. 3.3 Total PET and PET/CT Market Forecasts 43
48. 3.3.1 Revenue Forecasts 44
49. 3.3.2 Unit Shipment Forecasts 45
50. 3.3.3 Procedure Forecast 46
51. 3.3.4 Competitive Structure 47
52. 3.3.5 Market Share Analysis 49
53. 3.3.6 Future Directions for PET 51
54. 3.3.7 New PET Technology Platforms 52
55. 3.4 SPECT Market Forecasts 52
56. 3.5 Stand-Alone PET Market Forecasts 53
57. 3.5.1 Revenue Forecasts 53
58. 3.5.2 Unit Shipment Forecasts 54
59. 3.5.3 Market Share Analysis 54
60. 3.6 PET/CT Market Forecasts 54
61. 3.6.1 PET/CT Revenue Forecasts 55
62. 3.6.2 PET/CT Unit Shipment Forecasts 55
63. 3.6.3 PET/CT Market Share Analysis 55
64. 3.7 Products 55
65. 3.7.1 Gamma Medica 55
66. 3.7.2 Mallinckrodt 56
67. 3.7.3 Naviscan PET Systems 56
68. 3.7.4 Siemens Medical 56
69. 3.7.5 TeraRecon 56
70. 3.7.6 Toshiba America Medical Systems 56
71. 3.7.7 CTI Molecular Imaging Inc. 56
72. 3.7.8 GE Healthcare 56
73. 3.7.9 Philips Medical Systems 57
74. 3.7.10 MedImage Inc. 57
76. 4 PET/CT 58
77. 4.1 Strengths of CT and PET Scanning 58
78. 4.2 Combining CT's Strengths with PET Scanning 58
79. 4.3 Nuclear Medicine Safety Protocols 59
80. 4.4 PET Safety Protocols 60
81. 4.4.1 Radiation Safety 61
82. 4.4.2 Appropriate Shielding 62
83. 4.4.3 Radioactive Package Protocols 63
84. 4.5 Regulatory Requirements 64
85. 4.6 PET and SPECT Tracers 65
86. 4.6.1 FDG Centers 65
87. 4.7 PET Imaging 66
88. 4.8 PET and Cancer Staging 67
89. 4.9 PET/CT Reimbursement 67
91. 5 Hybrid Technology: PET/CT and SPECT/CT 69
92. 5.1 PET/CT 69
93. 5.2 SPECT/CT 69
94. 5.2.1 Blending of Technology Platforms 70
95. 5.2.2 SPECT vs. PET 70
97. 6 SPECT and SPECT/CT 73
98. 6.1 Single-Photon Emission Computed Tomography (SPECT) 73
99. 6.1.1 SPECT Imaging 73
100. 6.1.2 SPECT Instrumentation 73
101. 6.1.3 SPECT Market 74
102. 6.2 SPECT/CT 74
103. 6.2.1 Differences between PET and SPECT 74
104. 6.3 Potential Applications of SPECT/CT 74
105. 6.3.1 SPECT/CT in Cardiology 75
106. 6.3.2 Myocardial Perfusion Imaging 75
107. 6.3.3 Functional Brain Imaging 76
108. 6.3.4 SPECT/CT in General Nuclear Medicine 76
109. 6.3.5 SPECT/CT in Neurology 77
110. 6.3.6 Oncology Applications 77
111. 6.4 New Technology Platforms: SPECT 77
112. 6.4.1 Future Growth 77
114. 7 Clinical PET/CT for Oncology Applications 78
115. 7.1 Pulmonary Nodules 78
116. 7.2 Non-Small-Cell Lung Cancer 78
117. 7.3 Melanoma 79
118. 7.4 Lymphoma 79
119. 7.5 Colorectal Cancer 80
120. 7.6 Head and Neck Cancer 81
121. 7.7 Esophageal Cancer 81
122. 7.8 Breast Cancer 81
123. 7.9 Brain Cancer 82
124. 7.10 Prostate Cancer 83
125. 7.11 Ovarian Cancer 83
126. 7.12 Cervical Cancer 83
127. 7.13 Testicular Cancer 84
128. 7.14 Thyroid Cancer 84
129. 7.15 Pancreatic Cancer 84
130. 7.16 Trends in Clinical Use of PET/CT 84
131. 7.17 Development of PET/MRI 84
133. 8 Company Listings 86
135. Appendix 1. Radiopharmaceutical Diagnostic Imaging Agent Codes and PET Scan Services 87
138. LIST OF TABLES
140. Table 2.1: U.S. Medical Imaging Market Size, 2001 to 2010 9
141. Table 2.2: Global Medical Imaging Market Size, 2001 to 2010 9
142. Table 2.3: U.S. Healthcare Expenditures, 1999 to 2010 10
143. Table 2.4: U.S. Health Expenditures as a Percentage of GDP, 1999 to 2010 10
144. Table 2.5: U.S. User Expenditures for Medical Imaging Equipment and Related Products 10
145. Table 2.6: Millions of Americans Over 65 Years of Age, 2000 to 2050 11
146. Table 2.7: Hospital Survey 11
147. Table 2.8: U.S. Radiological Images Taken, 1999 to 2010 12
148. Table 2.9: Worldwide Market Share Medical Imaging and Diagnostic Companies 15
149. Table 2.10: U.S. Nuclear Medicine Procedures, 2002 to 2010 18
150. Table 2.11: PET Radioisotopes 32
151. Table 3.1: Type of Imaging Offered by Facility 37
152. Table 3.2: PET Procedures by Type 39
153. Table 3.3: PET Patient Studies Performed in U.S. 43
154. Table 3.4: Worldwide Dollar Sales of PET Imaging Systems, 2004 to 2011 44
155. Table 3.5: U.S. Dollar Sales of PET Imaging Systems, 2004 to 2011 44
156. Table 3.6: Average Selling Price for PET, U.S. and Worldwide, 2004 to 2011 45
157. Table 3.7: Unit Sales of PET Imaging Systems, U.S. and Worldwide, 2004 to 2011 45
158. Table 3.8: Installed Base of PET Imaging Systems, U.S., 2004 to 2011 46
159. Table 3.9: PET Procedure Volume, 2004 to 2011 46
160. Table 3.10: FDG Sales, 2004 to 2011 47
161. Table 3.11: SPECT Procedure Volume, 2004 to 2011 53
162. Table 3.12: U.S. SPECT Scanner Market Size and Growth, 2002 to 2010 53
163. Table 3.13: U.S. Stand-Alone PET Scanner Market Size and Growth, 2004 to 2011 53
164. Table 3.14: U.S. PET/CT Scanner Market Size and Growth, 2002 to 2010 55
165. Table 4.1: PET Applications Approved for Reimbursement by CMS 68
166. Table 5.1: SPECT and PET Hybrid Sales Percentages 70